Hormonal therapy for cancer

Jacinta, Abraham and Staffurth, John ORCID: https://orcid.org/0000-0002-7834-3172 2020. Hormonal therapy for cancer. Medicine 48 (2) , pp. 103-107. 10.1016/j.mpmed.2019.11.007

PDF - Accepted Post-Print Version Download (296kB)

Abstract

Hormone therapy is an effective and non-toxic therapy for oestrogen and progesterone receptor-positive breast cancer and for prostate cancer. Serum concentrations of oestradiol and testosterone are controlled by the hypothalamic-pituitary-gonadal pathway. Oestradiol is produced in premenopausal women from the ovaries, and in postmenopausal women by peripheral conversion of adrenal androgens by aromatase. In premenopausal women with breast cancer and men with prostate cancer, treatment is primarily achieved by castration. In postmenopausal women, selective oestrogen receptor modulators (e.g. tamoxifen) or aromatase inhibitors are used. Hormone therapy can be used to reduce the size of the primary cancer before radical surgery or radiotherapy, or to reduce the risk of recurrence. Hormone therapy is highly effective in patients with locally advanced or metastatic disease, with high response rates. Most patients eventually relapse with hormone-refractory disease and can be offered novel hormonal agents, chemotherapy or molecularly targeted agents.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	Elsevier
ISSN:	1357-3039
Date of First Compliant Deposit:	14 February 2020
Date of Acceptance:	14 January 2020
Last Modified:	07 Nov 2023 19:04
URI:	https://orca.cardiff.ac.uk/id/eprint/129672

Citation Data

Cited 3 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item